Clinical trials: sponsored by Sanofi
Psoriasis
A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis
This is a parallel, Phase 1, single center, 2-arm, double-blind, randomized, placebo-controlled with a ratio 2 active: 1 placebo study for treatment of mild to moderate psoriasis participants.
- Trial name
- NCT05453942
- Testing
- SAR441566
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Sanofi
Von Willebrand's Disease (VWD)
To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)
Primary Objective: -To characterize the pharmacokinetics (PK) of BIVV001 after a single intravenous (IV) administration, as assessed by factor VIII (FVIII) activity determined by the one-stage activated partial thromboplastin…
- Trial name
- NCT04770935
- Testing
- efanesoctocog alfa (BIVV001)
- Where
- 4 sites in United States, France
- Volunteers
- 6 people
- Sponsor
- Bioverativ, a Sanofi company
Chronic Rhinosinusitis With Nasal Polyps
Dupilumab in Chinese Adult Participants With CRSwNP
This is a parallel group, Phase 3, 2-arm study for treatment. The purpose of this study is to evaluate dupilumab subcutaneous (SC) injections compared to placebo in Chinese adult participants with CRSwNP, on a background therapy…
- Trial name
- NCT05878093
- Testing
- Dupilumab, Budesonide
- Where
- 18 sites in China
- Volunteers
- 63 people
- Sponsor
- Sanofi
Breast Cancer, Healthy Volunteers
Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women
Primary Objectives: To assess the excretion balance after oral and IV administration of [14C]-SAR439859 To assess PK of total radioactivity, [14C] -SAR439859 and its metabolite (M7) after IV administration of [14C]-SAR439859 and…
- Trial name
- NCT04940026
- Testing
- amcenestrant, [14C]-SAR439859 microtracer, [14C]-SAR439859
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza (Healthy Volunteers)
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older
Primary Objective: Immunogenicity: To describe the immune response induced by high-dose quadrivalent influenza vaccine (QIV-HD) and AdimFlu-S (QIS) by hemagglutinin inhibition (HAI) measurement method in all participants.
- Trial name
- NCT04537234
- Testing
- High-Dose Quadrivalent Influenza Vaccine, Standard-Dose Quadrivalent Influenza Vaccine
- Where
- 4 sites in Taiwan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Type 2 Diabetes Mellitus
iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
This was a parallel-group treatment, Phase 3, randomized, 2-arm study that assessed the efficacy and safety of iGlarLixi to IDegAsp in Chinese T2DM participants insufficiently controlled with oral antidiabetic drug(s).
- Trial name
- NCT05413369
- Testing
- Insulin glargine/Lixisenatide, IDegAsp, Metformin
- Where
- 60 sites in China
- Volunteers
- 582 people
- Sponsor
- Sanofi
Corona Virus Infection
Sarilumab COVID-19
Primary Objective: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult participants hospitalized with severe or critical Coronavirus Disease 2019 (COVID-19).
- Trial name
- NCT04327388
- Testing
- Sarilumab SAR153191
- Where
- 47 sites in Argentina, Brazil and 9 more
- Volunteers
- 420 people
- Sponsor
- Sanofi
Thyroid Cancer
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474…
- Trial name
- NCT00410761
- Testing
- ZD6474 (Vandetanib)
- Where
- 127 sites in United States, Australia and 22 more
- Volunteers
- 331 people
- Sponsor
- Genzyme, a Sanofi Company
Influenza, Healthy Volunteers
Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older
VAM00001 is a Phase I/II, randomized, modified double-blind, multi-center study. The purpose of this study is to compare 2 dose levels of Panblok H7 (dose 1 and dose 2 of rHA) with a standard squalene dose of adjuvant MF59 to…
- Trial name
- NCT05608005
- Testing
- Panblok + MF59 Dose 1, Panblok + MF59 Dose 2, Unadjuvanted Panblok Dose 3
- Where
- 16 sites in United States
- Volunteers
- 581 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Oesophageal Squamous Cell Carcinoma, Gastric Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years…
- Conditions
- Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT05104567
- Testing
- THOR-707, Pembrolizumab, Cetuximab
- Where
- 29 sites in United States, Belgium and 7 more
- Volunteers
- 138 people
- Sponsor
- Sanofi
Multiple Sclerosis
Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks
Primary Objective: Evaluate the relationship between ABCG2 mutation (rs2231142) and teriflunomide exposure, during 6-month treatment with teriflunomide 14 mg Secondary Objective: Characterize the safety (AEs, such as ALT…
- Trial name
- TERI-PK (NCT04410965)
- Testing
- TERIFLUNOMIDE
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Sanofi
Type 1 Diabetes
A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 Diabetes
Primary Objective: To demonstrate bioequivalence between insulin lispro given as SAR342434, 200 Units/ml test formulation (T) and insulin lispro 100 Units/ml reference formulation (R) after a single subcutaneous (SC) dose…
- Trial name
- NCT03903016
- Testing
- Insulin Lispro SAR342434
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Sanofi
Gaucher Disease, Splenomegaly, Acid SphingoMyelinase Deficiency
A Non-Interventional National Study in Pediatric Patients With Unexplained Enlarged Spleen
Primary Objective: To assess prevalence of Gaucher disease (GD) diagnosed in pediatric patients presenting with unexplained splenomegaly (SMG) after exclusion of first intention-diagnoses (e.g.
- Trial name
- OPPUS (NCT04845958)
- Where
- 40 sites in France
- Volunteers
- 60 people
- Sponsor
- Sanofi
Multiple Sclerosis
Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects
Primary Objective: To determine the excretion balance and systemic exposure of radioactivity after oral administration of [14C]-SAR442168.
- Trial name
- NCT04171310
- Testing
- SAR442168
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sanofi
Corona Virus Infection
A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19
Primary Objective: To evaluate the effect of SAR443122 relative to the control arm on the hyperinflammatory state as measured by C-reactive protein (CRP) levels in adult patients hospitalized with severe coronavirus disease 2019…
- Trial name
- NCT04469621
- Testing
- SAR443122
- Where
- 10 sites in Argentina, Brazil and 3 more
- Volunteers
- 68 people
- Sponsor
- Sanofi
Lymphoma
A Study of Isatuximab-based Therapy in Participants With Lymphoma
Primary Objectives: Phase 1 -To characterize the safety and tolerability of isatuximab in combination with cemiplimab in participants with relapsed and refractory classic Hodgkin's lymphoma (cHL), diffuse large B-cell lymphoma…
- Trial name
- NCT03769181
- Testing
- isatuximab SAR650984, cemiplimab REGN2810
- Where
- 20 sites in France, Italy and 5 more
- Volunteers
- 58 people
- Sponsor
- Sanofi
Healthy Volunteers
Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants
Primary Objective: To evaluate the impact of food on the pharmacokinetics (PK) of rilzabrutinib following single oral doses to healthy subjects.
- Trial name
- NCT04748926
- Testing
- rilzabrutinib SAR444671
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Principia Biopharma, a Sanofi Company
Coronavirus Infection
Hydroxychloroquine in Outpatient Adults With COVID-19
Primary Objective: To assess the effect of hydroxychloroquine versus placebo on nasopharyngeal SARS-CoV-2 viral load in outpatient adults with COVID-19 Secondary Objectives: To assess the effect of hydroxychloroquine versus…
- Trial name
- NCT04333654
- Testing
- Hydroxychloroquine SAR321068
- Where
- 7 sites in United States, Belgium and 2 more
- Volunteers
- 8 people
- Sponsor
- Sanofi
Influenza Immunization, Healthy Volunteers
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older
Primary Objective: To demonstrate that QIV-HD induced an immune response (as assessed by hemagglutination inhibition [HAI] geometric mean titers [GMTs] and seroconversion rates) that was superior to responses induced by QIV-SD…
- Trial name
- NCT04498832
- Testing
- High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD), Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)
- Where
- 10 sites in Japan
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Phenylketonuria
A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria
This is a single group Phase 1/Phase 2, 1-arm, open-label study with SAR444836, an adeno-associated virus (AAV) vector-mediated gene transfer of human phenylalanine hydroxylase (PAH), for the treatment of adult participants with…
- Trial name
- NCT05972629
- Testing
- SAR444836
- Where
- 11 sites in United States, Argentina and 3 more
- Volunteers
- 32 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.